TABLE 4.
Cost‐effectiveness of treatment strategies for hepatitis C virus infection among kidney waitlist candidates by fibrosis stage at waitlist addition
| Treatment strategy | cost, $ | Incremental cost, $ |
QALM | Incremental QALM |
ICER, $/ QALY |
Undiscounted life months |
5 y budget impact, $ |
|---|---|---|---|---|---|---|---|
| Overall | |||||||
| Treat posttransplant | 682 400 | 61.8 | 164.8 | 391 560 600 | |||
| Treat pretransplant | 735 700 | 53 300 | 65.6 | 3.9 | 162 800 | 164.5 | 419 087 100 |
| F0 | |||||||
| Treat posttransplant | 696 200 | 69.5 | 167.8 | 393 551 000 | |||
| Treat pretransplant | 736 000 | 39 800 | 68.5 | −1.1 | Dom | 164.0 | 418 573 200 |
| F1 | |||||||
| Treat posttransplant | 689 400 | 67.9 | 165.7 | 395 221 600 | |||
| Treat pretransplant | 732 200 | 42 800 | 68.6 | 0.7 | 722 800 | 164.3 | 419 620 700 |
| F2 | |||||||
| Treat posttransplant | 690 500 | 65.5 | 167.2 | 393 873 200 | |||
| Treat pretransplant | 741 000 | 50 500 | 69.1 | 3.6 | 167 200 | 166.1 | 421 481 700 |
| F3 | |||||||
| Treat posttransplant | 676 600 | 58.7 | 163.4 | 391 384 200 | |||
| Treat pretransplant | 736 500 | 59 900 | 67.5 | 8.8 | 82 000 | 164.3 | 418 446 000 |
| F4 | |||||||
| Treat posttransplant | 663 000 | 49.3 | 160.5 | 383 726 900 | |||
| Treat pretransplant | 731 500 | 68 500 | 54.1 | 4.7 | 173 800 | 163.2 | 416 710 350 |
Dom, dominated (more costly, and less effective); QALM, quality adjusted life month; ICER, incremental cost‐effectiveness ratio; QALY, quality adjusted life years.